Recruiting

Laser Ablation

Sponsor:

University Health Network, Toronto

Code:

NCT03650595

Conditions

Prostate Cancer

Low and Intermediate Risk Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

The TRANBERGCLS|Thermal Therapy

Study Details

Brief summary:

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.

Conditions

Prostate Cancer

Low and Intermediate Risk Prostate Cancer

Study ID

NCT03650595

Start date

Mar 29, 2018

Status verified date

Jun, 2026

Completion date

Jun 30, 2028

Anticipated

Primary completion date

Dec 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 40 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men 40-80 years of age
  • Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;)
  • Prostate cancer clinical stage T1c and T2
  • MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device
  • Size of MR visible tumor <20mm
  • Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy
  • Prostate specific antigen (PSA) level <15 ng/mL
  • IPSS, ICIQ-UI-SF, IIEF complete prior to procedure
  • Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.

Exclusion Criteria:

  • Medically unfit for focal therapy of the prostate
  • Patients who are unwilling or unable to give informed consent;
  • Patients who have received androgen suppression therapy
  • Patients who have received or are receiving chemotherapy for prostate carcinoma;
  • Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment
  • Patients who have undergone radiation therapy for prostate cancer or to the pelvis
  • Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);
  • Patients with a history of noncompliance with medical therapy and/or medical recommendations;
  • Patients who are unwilling or unable to complete the patient self-assessment questionnaires;
  • Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.
  • Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days;
  • Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)
  • Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study

Study Design

Enrollment

102 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Single arm prospective clinical trial

This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time

Interventions

The TRANBERGCLS|Thermal Therapy

MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy

Primary outcome measure

  • The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment) [ Time Frame: 6 months after treatment completion ]
  • The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment) [ Time Frame: 24 months after treatment completion ]

Central Contacts and Locations

Central contacts

Sangeet Ghai, MD

416-340-4800sangeet.ghai@uhn.ca

Kateri Corr, RPN

416-946-4501kateri.corr@uhn.ca

Locations

Sangeet Ghai, MD

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Contacts

Sangeet Ghai, MD

416-340-4656sangeet.ghai@uhn.ca

Kateri Corr, RPN

416-946-4501kateri.corr@uhn.ca

More Information

Sponsor

University Health Network, Toronto

Last update posted

Jun 5, 2026

Last verified

Jun, 2026

Keywords

  • MRI
  • Focal Laser Ablation
  • MR-Guided Focal Laser Ablation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2026-06-05.